Meeting
2012 ASCO Annual Meeting
A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).
Authors
Martin Schlumberger
Institut Gustave Roussy, Villejuif, France
Martin Schlumberger , Barbara Jarzab , Maria E. Cabanillas , Bruce Robinson , Furio Pacini , Douglas Wilmot Ball , Judith C McCaffrey , Kate Newbold , Roger Allison , Renato Martins , Lisa F. Licitra , Manisha H. Shah , Donald Bodenner , Rossella Elisei , Lynn A. Burmeister , Yasuhiro Funahashi , Rita Sellecchia , Corina Andresen , James P. O'Brien , Steven I. Sherman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT00784303
Citation
J Clin Oncol 30, 2012 (suppl; abstr 5591)
DOI
10.1200/jco.2012.30.15_suppl.5591
Abstract #
5591
Poster Bd #
32A
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma.
First Author: Steven O'Day
Poster
2017 ASCO Annual Meeting
A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
First Author: Jiaying Chen
Poster
2014 ASCO Annual Meeting
Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: An analysis of approximately 500 patients treated with lenvatinib across tumor types.
First Author: Ignace Vergote
Poster
2013 ASCO Annual Meeting
A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: angiopoietin-2 as a predictive marker for clinical outcomes.
First Author: Ignace Vergote